Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners by Moor, C.C. (Karen) et al.
Vol.:(0123456789) 
Lung 
https://doi.org/10.1007/s00408-018-0144-4
INTERSTITIAL LUNG DISEASE
Needs, Perceptions and Education in Sarcoidosis: A Live Interactive 
Survey of Patients and Partners
C. C. Moor1 · M. J. G. van Manen1 · P. M. van Hagen2 · J. R. Miedema1 · L. M. van den Toorn1 · Y. Gür‑Demirel1 · 
A. P. C. Berendse3 · J. A. M. van Laar2 · M. S. Wijsenbeek1
Received: 5 June 2018 / Accepted: 3 August 2018 
© The Author(s) 2018
Abstract
Objectives Sarcoidosis is a chronic, multisystem disease with often a major impact on quality of life. Information on unmet 
needs of patients and their partners is lacking. We assessed needs and perceptions of sarcoidosis patients and their partners.
Methods During patient information meetings in 2015 and 2017 in the Erasmus University Medical Center, we interviewed 
patients and partners using interactive voting boxes. Patients responded anonymously to 17 questions. Answers were pro-
jected directly on the screen in the room.
Results 210 patients and 132 partners participated. Sarcoidosis has a subjective significant impact on lives of both patients 
and partners. The vast majority of patients and partners feel regularly misunderstood because of the general unawareness of 
sarcoidosis. Many patients and partners experience anxiety. Three-quarters of patients would like to see more attention and 
support for their psychological problems. Additionally, more supportive care for partners of sarcoidosis patients is warranted. 
Interactive interviewing was considered educational (91%) and pleasant (84%).
Discussion This study improves awareness of needs and perceptions of patients with sarcoidosis and their partners. Sar-
coidosis leads to anxiety and psychological distress and impairs well-being of patients and their partners. Attention for 
psychological support, better disease education, and more supportive care for partners is warranted.
Background
Sarcoidosis is a heterogeneous, granulomatous disorder of 
unknown cause, most often localized in the lungs and lym-
phatic system. However, sarcoidosis can affect almost every 
organ. Therefore, disease presentation and behavior vary 
and can be unpredictable [1, 2]. Sarcoidosis often occurs in 
relatively young adults, between 20 and 50 years of age [2, 
3]. Quality of life (QoL) is often impaired due to burden of 
symptoms such as fatigue, pain, dyspnea, persistent cough, 
and reduced exercise intolerance. These symptoms can lead 
to stress, anxiety and depression, and social and physical 
limitations [4–7]. Side-effects of treatment and complica-
tions of disease can also negatively impact QoL [6–8]. Only 
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a few studies aimed to improve QoL in patients with sar-
coidosis; these studies were mainly focused on pulmonary 
rehabilitation [9, 10].
Although it is well-known that sarcoidosis is a disabling 
disease [7, 11], studies on patients’ needs and preferences in 
care are lacking. Also, to our knowledge, no currently avail-
able studies assessed whether sarcoidosis also influences 
well-being of partners or other close relatives.
Every year a multidisciplinary sarcoidosis patient meet-
ing takes place in the Erasmus University Medical Center 
Rotterdam in the Netherlands, aiming to provide up-to-date 
information and new insights on sarcoidosis to patients and 
their partners. All patients with confirmed sarcoidosis from 
the Erasmus University Medical Center are invited to visit 
these patient meetings. Several medical specialties involved 
in sarcoidosis care, and the Dutch sarcoidosis patient organi-
zation (sarcoidose.nl), organize and attend these meetings.
These meetings allow us to ask patients and partners mul-
tiple questions with the use of an interactive voting system. 
This system enables the attendants to directly see the aggre-
gated results, thereby providing live information about expe-
riences and needs of other patients and partners. A study 
in pulmonary fibrosis showed that the use of an interactive 
voting system is considered informative and appreciated by 
participants, and that it could be an efficient way to inform 
and educate patients and partners [12].
The aim of this study was to evaluate the needs and per-
ceptions of patients with sarcoidosis and their partners. 
Moreover, we assessed whether interactive interview-
ing could be used to enhance education in patients with 
sarcoidosis.
Methods
In 2015 and 2017 patients were interviewed during patient 
information meetings in the Erasmus University Medical 
Center, one of the two recognized sarcoidosis expert cent-
ers in the Netherlands. Patients and partners received vot-
ing boxes (TurningPoint 2008; Keepad Interactive, Sydney, 
Australia) at the start of the information meeting and voted 
anonymously. Participants were asked permission to use the 
data before the meeting started. Medical Ethical Committee 
approval was granted. In accordance with the study of van 
Manen et al. [12] the term “partners” comprised also other 
nearest and dearest. Fifteen questions were asked during the 
meetings in 2015 and 2017. Three questions, about organ 
involvement and the value of interactive voting, were added 
in 2017. Literature search, input from patients, physicians, 
and specialist nurses were used to compose the questions. 
Moreover, the validated Generalized Anxiety Disorder-
Single Item (GAD-SI) was administered [13]. Questions 
were shown on a big screen and read out loud by one of the 
speakers. Subsequently, a 10 s countdown was projected on 
the screen to provide enough time for participants to vote. 
Afterwards, answers of participants were shown on the 
screen and directly discussed with the audience. Data were 
exported and analyzed in Microsoft Excel 2010 afterwards. 
All data are presented as % (n).
Results
A total of 210 sarcoidosis patients and 132 partners partici-
pated in the interactive voting during the two information 
meetings. Of the 342 participants, 40 people attended both 
meetings.
In 2017, patients (n = 104) were asked to report which 
organs were involved in their sarcoidosis; 47% of patients 
reported multi-organ involvement, 34% reported only 
pulmonary involvement, and a small minority of patients 
reported respectively only neurological involvement (7%), 
eye involvement (6%), joint/muscle involvement (3%), car-
diac involvement (3%), and skin involvement (1%).
The symptoms that affected sarcoidosis patients most 
were fatigue, painful joints and/or muscles, and breathless-
ness. Furthermore, cough, skin manifestations, ocular com-
plaints, and depressive symptoms were reported by a minor-
ity of patients as their most disabling symptom (Fig. 1).
Sarcoidosis had a huge impact on the lives of the major-
ity of patients and their partners in a similar manner; almost 
three-fourth of patients reported (very) much influence on 
their daily life (Fig. 2).
In the vast majority of patients and partners the GAD-SI 
score was elevated, which indicates high levels of anxiety 
(Fig. 3). The answers “more than half of the days” (19%, 
n = 50) and “almost every day” (29%, n = 74) based on 
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Fig. 1  Patients’ response to the question “What symptom of sarcoido-
sis affects you the most?”
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the GAD-SI questionnaire are considered suggestive of 
having a generalized anxiety disorder (GAD) [13]. Almost 
three-quarters of patients (74%, n = 132) would like to see 
more attention and support for their psychological prob-
lems. One-third of patients (33%, n = 59) stated that they 
missed psychological support in standard care, whereas 
41% (n = 73) of patients would only like to receive psycho-
logical care when they specifically ask for it. A minority 
of patients reported no psychological issues (18%, n = 32).
In addition, many participants experienced some degree 
of misunderstanding, because of the general unawareness 
of sarcoidosis. Figure 4 shows that partners seem to expe-
rience even more misunderstanding than patients.
The main needs in care of patients with sarcoido-
sis were easy access to an expert center for sarcoidosis 
(36%, n = 67) and receiving adequate information about 
the disease (41%, n = 78). Additionally, the importance of 
practical and emotional support, and contact with peers 
were mentioned by patients. Also, 41% (n = 53) of partners 
thought that there should be more support for the partners 
of sarcoidosis patients.
Furthermore, we asked patients questions about their 
opinion on eHealth. The majority of participants (70%, 
n = 132) would like to keep track of their data and symp-
toms on the internet. Almost all patients (92%, n = 170) 
would be willing to measure lung function at home to opti-
mize treatment.
Most patients and partners rated the information meet-
ing as very useful (86%, n = 237). About one-third of par-
ticipants felt more confident after the meeting (Fig. 5). 
In 2017, 84% (n = 128) of participants appreciated seeing 
the answers of other participants immediately after each 
question, and 91% (n = 136) considered the interactive 
interviewing educational.
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Fig. 2  Subject responses to the questions “What is the influence of 
sarcoidosis on your life at this moment?” and “What is the influence 
of having a partner with sarcoidosis on your life at this moment?”
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Fig. 3  Experience of anxiety of both patients and partners based on 
the Generalized Anxiety Disorder-single item questionnaire [13] 
“How often in the past 2 weeks did you have trouble relaxing?”
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Fig. 4  Participants’ responses to the question “How often do you 
experience misunderstanding because people do not know what sar-
coidosis is?”
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Discussion
This study shows the major psychological and social impact 
of sarcoidosis, not only on patients but also on their part-
ners. Education and psychological support are reported as 
important unmet needs. Furthermore, the study shows that 
patients and partners appreciate the interactive voting system 
and consider it informative. Interactive voting might be a 
suitable method to facilitate discussion with patients and to 
educate and support them at the same time.
The Patient Voice in Care
The importance of patient participation and shared decision 
making in healthcare has been increasingly acknowledged 
during the last years [14]. Although studies on patient partic-
ipation in sarcoidosis are scarce, it is appreciated that engag-
ing patients in care could lead to better clinical outcomes 
and treatment adherence, especially because sarcoidosis is 
such a multidimensional disease [11]. Recently, the Nether-
lands institute for health services research showed that 75% 
of sarcoidosis patients considers shared decision making 
important [15]. However, to allow for shared decision mak-
ing, patients must be well informed and physicians should 
have better insights into patients’ perception of disease and 
preferences in care. The data of this study can be used to bet-
ter address the needs of patients with sarcoidosis and their 
partners, and to improve daily care.
Fatigue
Most patients in our study report fatigue as the symptom 
which affects them most. This is in accordance with previ-
ous studies, in which fatigue was the most burdensome and 
frequent symptom in sarcoidosis [16, 17], with a negative 
impact on QoL [8, 11, 18]. Fatigue often persists, even if 
sarcoidosis is treated well and no other sarcoidosis disease 
activity can be found [11]. A few small studies showed effect 
of neurostimulants or pulmonary rehabilitation on fatigue 
[9, 10, 19, 20], however, larger randomized trials with spe-
cific fatigue interventions are lacking. Design of such trials 
is complicated, because sarcoidosis-associated fatigue is a 
multidimensional, complex problem with unknown etiology 
[17, 21]. Besides, fatigue in sarcoidosis is related to depres-
sive symptoms and sleep disturbance [17, 18, 22, 23]. As 
also illustrated by the results of this study, fatigue remains 
a major problem for patients. A multidisciplinary approach 
towards sarcoidosis-associated fatigue is needed and should 
be subject for future research.
Influence of Sarcoidosis on Daily Life
Our study shows that sarcoidosis has a major influence on 
patients’ daily lives. It is well established that sarcoidosis 
has a huge impact on patients; health status and QoL are 
lower than in the normal population [4, 7, 24]. This study is 
the first to show that sarcoidosis also has a major impact on 
the daily lives of partners of sarcoidosis patients.
Many patients feel that they are not taken serious by rela-
tives and friends. The reason for this might be that sarcoido-
sis is often not visible [11]. In our study, many patients and 
partners experience misunderstanding because of the gen-
eral unawareness of sarcoidosis in society. Patients often 
have non-specific symptoms, such as fatigue, depression, 
reduced exercise capacity, or pain, which are difficult to 
quantify. This could contribute to incomprehension of the 
impact of sarcoidosis, and lead to reduced labor force par-
ticipation, social isolation, and disturbed relationships [4, 
11, 25]. Improving general awareness about sarcoidosis and 
acknowledging the impact of sarcoidosis on many aspects 
of life, could possibly help sarcoidosis patients and partners 
to feel better understood.
Psychological Problems
Anxiety, stress, and depressive symptoms are common 
problems in sarcoidosis. In our study, the vast majority of 
patients experience some level of anxiety [13]. In literature, 
prevalence of depressive symptoms in sarcoidosis ranges 
from 27 to 66% and prevalence of anxiety ranges from 5 to 
32% [5, 6, 23, 26, 27]. Severe disease, multi-organ involve-
ment and dyspnea are associated with more depressive 
symptoms [26, 27]. However, the design of our study does 
not permit looking at such a correlation. Patients’ percep-
tion of disease, independent of disease status, might lead 
to anxiety and depression [27]. Disease chronicity, unpre-
dictable course, and uncertain future perspectives can also 
impair emotional well-being [23]. In daily practice, these 
0
10
20
30
40
50
60
More confident Less confident No change No opinion
Su
bj
ec
ts
 %
 (n
=2
69
)
Fig. 5  Feelings of patients and partners at the end of the meeting
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aspects are often neglected, and more recognition and tai-
lored interventions should be stimulated. Examples of pos-
sible interventions include cognitive behavioral therapy or 
psychological counseling [11, 24].
Anxiety in Partners
Strikingly, not only patients but also two-third of partners 
experience anxiety, 20% of them almost every day. In other 
chronic diseases, such as cancer, dementia, and rheuma-
toid arthritis, it has been acknowledged that many partners 
encounter psychological distress and have a decreased QoL 
[28]. Some studies showed that caregivers are even more 
distressed than patients, and that depression of patients 
was significantly associated with depression of their part-
ners [28–30]. Partners of sarcoidosis patients in our study 
report more anxiety and misunderstanding than partners of 
idiopathic pulmonary fibrosis (IPF) patients as reported pre-
viously [12]. This is remarkable when considering the pro-
gressive nature of disease and associated severely reduced 
life expectancy in IPF.
Currently, there are different questionnaires available 
which evaluate well-being, anxiety, and depressive symp-
toms of (informal) caregivers [31, 32]. In the light of the 
results of our study, it should be considered to incorporate 
such questionnaires in future care and studies, to gain more 
insight in QoL of partners of patients with sarcoidosis, and 
its effect on well-being of the patient.
Preferences in Care
Many partners of sarcoidosis patients in our study think that 
partners should receive more care. This is in line with stud-
ies assessing needs in partners of patients with other chronic 
illnesses [28, 30]. One of the options mentioned in literature 
is to invite partners more actively for outpatient clinic visits, 
encouraging them to ask questions or express concerns, and 
involve partners in decision making [28].
Clinicians tend to have more attention for physical param-
eters than psychological issues in patients with sarcoidosis 
[23]. This is in accordance with findings from our study, in 
which the majority of patients would appreciate more atten-
tion for psychological care. Furthermore, patients report the 
importance of access to an expert center, practical support, 
and contact with other patients. Patient organizations can 
also play an important role in facilitating contact with expert 
centers, information, and peer support.
Home Monitoring
Use of eHealth technologies has been increasing in recent 
years, and eHealth studies show promising results for 
improving quality of care [33]. The majority of patients in 
our study wish to keep track of their symptoms and manage 
their personal data at home using an internet tool. Further-
more, most patients in the current study are also willing 
to measure lung function at home. These are encouraging 
results for future care and trials, because a recent study in 
patients with newly diagnosed sarcoidosis showed that home 
spirometry was feasible and allowed for early detection of 
steroid treatment effects [34]. Home monitoring of lung 
function, symptoms, and side-effects, can help physicians 
to enhance individually tailored treatment by minimizing 
side-effects, maximizing effects and engaging patients in 
care [34].
Education
One of the main unmet needs in sarcoidosis care revealed in 
this study is the need for more information about the disease. 
In a recent government survey about chronic lung diseases, 
more than half of Dutch sarcoidosis patients reported that 
they cannot find sufficient information about their disease 
and its prospects [15]. This is one of the reasons that sar-
coidosis patient information meetings are organized every 
year. However, literature about the best method to provide 
information to patients with sarcoidosis is scarce. Drent and 
colleagues [11] state that the complex etiology of sarcoidosis 
and its variability make it complicated to provide adequate 
information, and that “affective communication” probably 
makes it easier for patients to remember medical informa-
tion. In the current study, one-third of patients felt more 
secure after the information meeting and the vast majority of 
patients appreciated live interactive interviewing, showing 
that this may be a promising method to enhance education 
of patients and partners.
Limitations
This study has of course limitations. Because of the inter-
active voting system, no specific patient characteristics are 
available, such as age, gender, and disease duration. Organ 
involvement was self-reported by patients and could not be 
verified. Furthermore, this was a single center study. Despite 
these limitations, we believe that the results are relevant for a 
broader group of sarcoidosis patients. We invited all patients 
with confirmed sarcoidosis of the Erasmus Medical Center, 
including patients with a wide spectrum of disease manifes-
tations and severity. A small minority of patients attended 
both the 2015 and 2017 meeting. However, because the total 
group of participants is large, the estimated effect of overlap 
in data is only small. Furthermore, not all patients answered 
all questions. Reasons for not answering could be prefer-
ence not to answer certain questions or being too late to 
respond. Therefore, we expressed all results as n (%), since 
the response rate might differ per question.
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Conclusion
This study improves awareness of needs and perceptions of 
both patients and their partners in sarcoidosis. Sarcoidosis 
not only leads to anxiety and psychological distress and 
impaired well-being in patients, but also in their partners. 
Therefore, attention for psychological support, better disease 
education, and more care for partners is warranted. Besides 
the ongoing need for improvement of disease modifying 
agents, future research should also focus on patient-centered 
programs to relieve distress and improve QoL for both sar-
coidosis patients and their partners.
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